2.14

2.14% 0.04

Inovio Pharmaceuticals Inc (INO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.10

Offen:

$2.12

24-Stunden-Volumen:

481.77K

Relative Volume:

0.79

Marktkapitalisierung:

$78.29M

Einnahmen:

$832.00K

Nettoeinkommen (Verlust:

$-135.12M

KGV:

-0.3514

EPS:

-6.09

Netto-Cashflow:

$-124.69M

1W Leistung:

+7.25%

1M Leistung:

+11.72%

6M Leistung:

-48.93%

1J Leistung:

-78.89%

1-Tages-Spanne:

$2.03

$2.175

1-Wochen-Bereich:

$1.98

$2.27

52-Wochen-Spanne:

$1.42

$12.33

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Firmenname

Inovio Pharmaceuticals Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (665)

Telefon

(858) 410-3134

Adresse

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Mitarbeiter

134

Twitter

@inoviopharma

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

INO's Discussions on Twitter

Vergleichen Sie INO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INO Inovio Pharmaceuticals Inc	2.135	73.35M	832.00K	-135.12M	-124.69M	-6.09
ONC Beone Medicines Ltd Adr	251.99	25.76B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	448.83	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.3401	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.72	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	494.56	65.13B	14.09B	4.50B	2.96B	39.28

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-14	Eingeleitet	Stephens	Overweight
2024-01-25	Hochstufung	Oppenheimer	Perform → Outperform
2022-11-09	Herabstufung	Maxim Group	Buy → Hold
2022-11-01	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-19	Fortgesetzt	RBC Capital Mkts	Sector Perform
2022-05-11	Herabstufung	Oppenheimer	Outperform → Perform
2022-01-21	Hochstufung	BofA Securities	Underperform → Neutral
2021-12-29	Fortgesetzt	Jefferies	Hold
2021-09-10	Herabstufung	BofA Securities	Neutral → Underperform
2021-06-24	Eingeleitet	Jefferies	Hold
2021-03-23	Eingeleitet	BofA Securities	Neutral
2021-02-12	Eingeleitet	Oppenheimer	Outperform
2020-11-17	Herabstufung	ROTH Capital	Neutral → Sell
2020-11-10	Hochstufung	ROTH Capital	Sell → Neutral
2020-09-28	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2020-09-28	Hochstufung	Maxim Group	Hold → Buy
2020-07-01	Herabstufung	Maxim Group	Buy → Hold
2020-07-01	Herabstufung	ROTH Capital	Neutral → Sell
2020-06-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-06-26	Herabstufung	Stifel	Buy → Hold
2020-05-21	Eingeleitet	The Benchmark Company	Buy
2020-04-30	Herabstufung	ROTH Capital	Buy → Neutral
2020-03-13	Herabstufung	Piper Sandler	Overweight → Neutral
2020-03-13	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-12-19	Eingeleitet	ROTH Capital	Buy
2018-02-15	Bestätigt	Maxim Group	Buy
2017-10-18	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-06	Eingeleitet	Citigroup	Buy
2017-06-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2017-05-24	Bestätigt	Maxim Group	Buy
2017-03-16	Hochstufung	Maxim Group	Hold → Buy
2017-03-16	Herabstufung	Piper Jaffray	Overweight → Neutral

Alle ansehen

Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten

May 30, 2025

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

May 30, 2025

May 27, 2025

Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia

May 27, 2025

May 23, 2025

Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada

May 23, 2025

May 22, 2025

Inovio shareholders approve board nominees and proposals - Investing.com Australia

May 22, 2025

Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN

May 15, 2025

May 14, 2025

Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus

May 14, 2025

Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria

May 14, 2025

INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus

May 14, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025

Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus

May 14, 2025

Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks

May 14, 2025

Inovio stock holds $12 target, JMP affirms Market Outperform By Investing.com - Investing.com Canada

May 14, 2025

Inovio stock holds $12 target, JMP affirms Market Outperform - Investing.com Australia

May 14, 2025